Mobility, Comfort & Healthy Aging
- Patient
- Redacted
- Species
- Canine
- Age
- Redacted
- Focus
- Mobility, comfort and healthy aging
Protocol overview
Why this protocol exists
The goal is quality of life. This advanced-geriatric patient has age-related orthopedic disease and reduced mobility. The immediate priority is comfort and movement.
The protocol focuses on the direct drivers of discomfort. A narrow foundation is introduced one compound at a time, so a change in comfort, appetite or energy can be traced to a single variable. Additional compounds remain in reserve until a specific need emerges and the foundation is well tolerated.
Primary goals
- Reduce chronic joint inflammation
- Improve hip mobility and walking ability
- Support connective tissue repair
- Improve comfort and willingness to move
- Preserve muscle function and overall quality of life
Protocol at a glance
| Compound | Primary role | Tier |
|---|---|---|
| BPC-157 / KPV | Tissue repair and inflammation control | Core foundation |
| TB-500 | Connective tissue remodeling and flexibility | Core foundation |
| SS-31 (Elamipretide) | Mitochondrial energy and cellular longevity | Consider if needed |
| ARA-290 | Nerve protection and chronic pain relief | Consider if needed |
MOTS-c duplicates the mitochondrial role assigned to SS-31. Dihexa lacks enough canine safety evidence for this case. Neither appears in the starting foundation.
Starting protocol
Core foundation
These compounds carry the mobility and comfort plan. Each is introduced and observed separately.
BPC-157 / KPV
Foundational tissue repair and inflammation control
BPC-157 and KPV form the starting foundation. Chronic inflammation contributes to pain, stiffness, slower healing and declining mobility in older dogs. BPC-157 supports tissue repair. KPV addresses excessive inflammatory signaling.
Together they support arthritic joints, tendons, ligaments, muscle recovery, gastrointestinal health and systemic inflammation. The combination is intended to support damaged tissues while reducing inflammatory stress.
Expected benefits
- Improved comfort
- Better mobility
- Reduced stiffness
- Improved recovery after activity
- Increased willingness to walk
TB-500
Connective tissue remodeling and flexibility
TB-500 supports connective tissue remodeling and flexibility throughout the musculoskeletal system. Its role is improved tissue function and easier movement over time.
The rationale is strongest for senior dogs with arthritis, muscle loss, chronic orthopedic disease and reduced flexibility.
Expected benefits
- Improved stride length
- Better flexibility
- Increased willingness to exercise
- Healthier connective tissue
- Improved recovery from daily activity
Held in reserve
Gated escalation
These candidates remain outside the starting protocol. A reviewing veterinarian may add one after the foundation is tolerated and the specific indication is present. The added compound starts at the low end and is observed before another change is made.
SS-31 (Elamipretide)
Mitochondrial energy and cellular longevity
Persistent low energy, weakness or poor recovery that remains after the foundation is established.
SS-31 targets mitochondrial function, cellular energy production and oxidative stress. Canine dosing is extrapolated from human data, so it remains a reserve option.
Potential benefits
- Increased daily energy
- Better endurance
- Stronger muscles
- Improved recovery
- Support for healthy aging
ARA-290
Nerve protection and chronic pain relief
Nerve-driven pain or sensitivity that remains after the foundation is established.
Chronic arthritis can sensitize nerves over time. ARA-290 activates tissue-protective pathways and reduces inflammatory signaling associated with chronic pain. It does not stimulate red blood cell production. Formal canine evidence remains limited.
Potential benefits
- Reduced chronic pain
- Healthier nerve function
- Reduced inflammatory signaling
- Greater comfort during walking
Sequencing
Suggested treatment progression
Compounds are introduced individually so tolerance and effect can be attributed clearly. The next agent begins after the current step is well tolerated.
| Step | Action | Focus |
|---|---|---|
| Step 1Weeks 1-2 | Start BPC-157 / KPV alone | Establish tolerance. Begin reducing inflammation and stiffness. |
| Step 2Week 2-3+ | Add TB-500 after the foundation is well tolerated | Support connective tissue, flexibility, stride and recovery. |
| EscalationOnly if warranted | Consider SS-31 or ARA-290, one at a time | Address one specific unmet need after the foundation is established. |
Monitoring
Expected timeline
- Easier rising from rest
- Improved walking
- Less stiffness
- Increased comfort
- Greater willingness to move
- Increased activity
- Improved mobility
- Better recovery after walks
- Improved quality of life
- Better maintenance of muscle mass
- Steadier day-to-day comfort
- Healthier aging
Clinical limits
Safety profile
Most compounds in this sample lack FDA approval as veterinary medications. The protocol starts at the low end and changes according to tolerance under veterinary supervision.
- BPC-157 / KPV
- Veterinary experience supports use for soft tissue healing and inflammation. Mild injection-site irritation is the most commonly reported adverse effect. Serious events have been uncommon.
- TB-500
- Used in equine and companion animal medicine for connective tissue support. Clinical experience suggests strong tolerability. Long-term controlled canine studies remain limited.
- SS-31 (Elamipretide)
- Human trials and animal studies report a strong safety profile. Its mechanism targets mitochondrial function. Canine dosing remains an extrapolation.
- ARA-290
- Human studies report a favorable safety profile. It was designed to activate tissue-protective pathways without increasing red blood cell production. Formal canine evidence remains limited.
Clinical conclusion
Overall assessment
This protocol narrows to the compounds that directly serve comfort and mobility. The two-compound foundation carries the strongest evidence-to-risk profile for the case. Healthy-aging candidates remain gated options, giving the reviewing veterinarian a focused plan.
Individual introduction keeps changes in comfort, appetite and energy attributable to one variable. Each step begins at the low end and advances according to tolerance. Periodic examinations and routine laboratory monitoring guide the plan as the patient’s needs change.